Jump to content

Australian men hopeful for quick announcement on Zytiga (abiraterone)


Recommended Posts

Australian men hopeful for quick announcement on Zytiga


In its budget announcement on 14 May 2013, the Australian government announced $691 million over five years in new listings or amendments to the Pharmaceutical Benefits Scheme (PBS).

The most pressing drug listing before the PBS is the advanced prostate cancer drug Zytiga, also called abiraterone.  Not only does Zytiga extend life for many men, it gives a much higher quality of life than other treatments. 

The government's own expert committee, the Pharmaceutical Benefits Advisory Committee (PBAC), recommended in November 2012 that Zytiga (abiraterone) be placed in the PBS, so it is available to men who have failed the chemotherapy drug Taxotere (docetaxel). 

Zytiga awaiting cabinet approval


The next step is cabinet approval. The Federal Minister for Health, Tania Pilberseck would have to recommend to cabinet that the drug be listed on the PBS.

If you are one of the thousands of men who stand to gain a longer, higher quality life from this drug, now or in the future, or someone who cares for such a man, it is time to think about writing to the Minister about a quick, humane decision.

The PCFA (Prostate Cancer Foundation of Australia) that we are affiliated with, and canSpeak have already sent such a letter to the Minister urging immediate action. Read that letter here.
Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...